Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026

Eli Lilly has dominated the GLP-1 market with Mounjaro and Zepbound, driving a 39% share-price gain in 2025, but its valuation appears stretched with a P/E of ~50 versus the S&P 500's ~28. Novo Nordisk beat Lilly to a GLP-1 pill in early 2026, and Lilly plans its own oral formulation, limiting the longevity of Lilly's advantage. Pfizer — whose internal GLP-1 program failed — trades at a low P/E (~15) but has pursued an acquisition and a distribution partnership for an external GLP-1 pill, positioning it as a lower-valuation turnaround play for investors seeking exposure to the GLP-1 opportunity.

Analysis

Market structure: GLP-1 winners over the next 12–24 months are incumbents with both shot and pill strategies (NVO, LLY but increasingly NVO on pills) and scale players that can buy-in fast (PFE via M&A/partnerships). Losers are niche developers without commercialization reach and higher-cost incumbents whose ASPs face 10–30% downward pressure as oral competition and payer negotiation intensify. Volatility will concentrate in equities and single-name options of NVO/LLY/PFE; credit spreads for high-quality pharmas should compress modestly as cash flows stabilize.

Risk assessment: Tail risks include a major safety signal or aggressive U.S./EU pricing intervention (low-probability 5–15% each) that could cut revenues 20–40% for exposed names. Immediate (days) risks: earnings/quarterly sales vs. consensus; short-term (weeks–months): regulatory decisions and payer formulary announcements; long-term (1–3 years): patent expiries and generics. Hidden dependencies: payer gross-to-net dynamics, manufacturing API scale for oral GLP-1s, and hospital/retail distribution agreements.

Trade implications: Favor value/optionality in PFE over multiple-rich LLY. Implement dollar-neutral pair trades (long PFE / short LLY) for 6–12 months and use 12–18 month call LEAPS on PFE via a 15–25% OTM call spread to cap cost. Use short-dated (3–6 month) puts on LLY to hedge event risk and trim growth-biotech cyclicality; rotate 2–5% portfolio weight from pure growth biotechs into diversified pharma.

Contrarian angles: Consensus underprices Pfizer’s M&A and distribution optionality — a successful partnered pill or tuck-in could re-rate PFE by 20–40% in 12–24 months. Conversely, the market may be underestimating rapid payer steering to lower-cost oral GLP-1s, which could compress LLY/NVO revenue growth faster than models assume. Historical parallel: rapid margin erosion in statins post-generic shows share can shift quickly once oral commoditization occurs, creating asymmetric downside for high-multiple growers.

Key Decisions for Investors

• Establish a 2–3% long position in PFE within the next 10 business days; add another 1–2% on any >10% pullback or on announced acquisition/partnered-pill approval. Thesis: PFE trades at ~P/E 15 with optionality from partnerships/M&A.
• Initiate a dollar-neutral pair trade: long PFE (2% portfolio) and short LLY (1.5% portfolio) for a 6–12 month horizon; target a 15% spread compression to exit or rebalance if either leg moves >25% intraday.
• Buy PFE 12–18 month call spread 15–25% OTM risking no more than 0.75–1.0% of portfolio to capture rerate optionality while capping premium paid.
• Purchase 3–6 month puts on LLY 10–15% OTM sized to 0.5–1.0% of portfolio as insurance against adverse GLP-1 safety/coverage outcomes; if no adverse event and LLY holds, sell into 20–30% premium decay.
• Monitor three catalysts over the next 30–90 days and act: (1) FDA/EMA filings or partner approval status for oral GLP-1s, (2) quarterly sales vs. consensus for LLY/NVO/PFE, (3) major payer formulary decisions — increase hedges if negative surprises exceed 10–15% sales miss.